10 位分析师将 Syndax Pharmaceuticals（纳斯达克股票代码：SNDX）评为“适度买入”，平均目标价为 35.33 美元;TD 联强国际 （SNX） 10 analysts rate Syndax Pharmaceuticals (NASDAQ:SNDX) as "Moderate Buy" with an average price target of $35.33; TD SYNNEX (SNX)
辛达克斯制药公司 (NASDAQ:SNDX) 获得了十位分析师的"中等购买"评级,平均目标价格为35.33美元. Syndax Pharmaceuticals (NASDAQ:SNDX) holds a "Moderate Buy" rating from ten analysts, with an average price target of $35.33. 该公司侧重于癌症治疗,其机构投资大幅增加。 The company, focusing on cancer therapies, has seen significant institutional investment increases. 同时,TD SYNEX(SNX)更新了Q4收入指南,预测EPS为2.80至3.30美元,收入估计数在149亿至157亿美元之间。 Meanwhile, TD SYNNEX (SNX) updated its Q4 earnings guidance, projecting EPS of $2.80 to $3.30, with revenue estimates between $14.9 billion and $15.7 billion. 据该公司报告,Q3收入为1.786亿美元,超过预期。 The company reported Q3 earnings of $178.6 million, exceeding expectations.